CN102188429A - Medicinal composition for treating diabetes - Google Patents
Medicinal composition for treating diabetes Download PDFInfo
- Publication number
- CN102188429A CN102188429A CN2011101319260A CN201110131926A CN102188429A CN 102188429 A CN102188429 A CN 102188429A CN 2011101319260 A CN2011101319260 A CN 2011101319260A CN 201110131926 A CN201110131926 A CN 201110131926A CN 102188429 A CN102188429 A CN 102188429A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- metformin hydrochloride
- bromocriptine
- diabetes
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a medicinal composition for treating diabetes, which comprises bromocriptine and metformin hydrochloride. In the medicinal composition for treating diabetes, the dose of a main medicine is small; and compared with other compound preparations of metformin hydrochloride, the side effect is reduced greatly, patients can taken the medicinal composition for a long time, and the obedience in the patients is high. In addition, the medicinal composition also has the advantage that the medicine price is lower than other metformin hydrochloride compound preparation treatment medicines.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of pharmaceutical composition for the treatment of diabetes.
Background technology
The up-to-date Epidemiological study of China shows: the prevalence of the adult's diabetes more than 20 years old is 9.7% (male 10.6%, and the women 8.8%), and the total number of persons of diabetics has reached 9.24 thousand ten thousand people, is the world the highest country of diabetics number.In addition, the prevalence of prediabetes is that 15.5% (male 16.2%, the women 14.9%), total number of persons has reached 100,000,000 482 ten thousand people, therefore there is the type 2 diabetes mellitus patient of a large amount of new diagnosis every year in China, to effective management of this part crowd, be to reduce the important step that causes permanent disability and death because of diabetic complication.
It is up to standard that present main treatment to the type 2 diabetes mellitus patient is still blood sugar control.Metformin hydrochloride is the medicine that the type 2 diabetes mellitus patient is newly diagnosed in the first-elected treatment of international guidelines, it by suppressing liver glyconeogenesis and impel of the picked-up utilization of periphery insulin target tissue to glucose, to improve the insulin sensitivity of body, it can obviously improve patient's anti-sugar amount and hyperinsulinemia, reduces blood plasma free fatty acid and triglyceride levels.
Bromocriptine is a dopamine receptor agonist, be mainly used in amenorrhea and the galactorrhea of treatment due to the hyperprolactinemia clinically, and female acyesis, also can be used for Parkinsonism, find to follow the decline of lactotropin when finding bromocriptine treatment prolactinoma complication with diabetes patient in a large amount of clinical practices use, blood glucose is also reduced to normally; No matter be that insulin dependent diabetes mellitus (IDDM) (IDDM) or non-insulin-dependent diabetes mellitus (NIDDM) all can make blood glucose significantly reduce, show that bromocriptine has clear and definite blood sugar reducing function.
In clinical practice at present, for not relying on diet merely, temper effective control hyperglycemia and use sulfonylurea separately or type 2 diabetes mellitus patient that metformin can not fine blood sugar control, the doctor also often cooperates sulfonylurea hypoglycemic agent with administration with metformin, secular clinical practice result shows: the medication diversity ratio of diabetics is bigger, combination drug and dosage also vary with each individual, such composite reagent comparatively frequent problem that the appearance curative effect is not obvious or side effect is bigger when the treatment Most patients simultaneously, particularly hypoglycemic reaction can appear, digestive tract reaction, side reactions such as anaphylaxis have influenced quality of life of patient greatly.Therefore seek a kind of compound hypoglycemic agent that can overcome existing medicine problem and seem extremely important, and this series products will have boundless market prospect.
By retrieval, find no the pertinent literature and the patent report that close compound recipe bromocriptine and metformin hydrochloride pharmaceutical composition.
Summary of the invention
It is obvious that technical problem to be solved by this invention provides a kind of curative effect, the pharmaceutical composition of the treatment diabetes that side effect is little.
For solving the problems of the technologies described above, the technical solution used in the present invention is as follows:
A kind of pharmaceutical composition for the treatment of diabetes, it comprises bromocriptine and metformin hydrochloride.
The pharmaceutical composition of above-mentioned treatment diabetes also comprises acceptable accessories, makes peroral dosage form.
Wherein, described dosage form is any one solid dosage forms in capsule, gastric soluble tablet, enteric coatel tablets and the slow releasing tablet.
Wherein, described adjuvant comprises filler, adhesive, disintegrating agent, lubricant, wetting agent or slow releasing agent.
Wherein, described filler is the mixture of any one or two or more arbitrary proportions in lactose one water thing, microcrystalline Cellulose, mannitol, dextrin, Icing Sugar and the starch.
Wherein, described adhesive is the mixture of any one or two or more arbitrary proportions of hydroxypropyl emthylcellulose, hydroxypropyl cellulose, starch slurry, gelatin and polyethylene glycol 6000.
Wherein, described disintegrating agent is the mixture of any one or two or more arbitrary proportions in cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium and the polyvinylpolypyrrolidone.
Wherein, the mixture of any one in described lubricant sodium stearyl fumarate, micropowder silica gel, magnesium stearate and the sodium laurylsulfate or two or more arbitrary proportions.
Wherein, described wetting agent is the mixture of any one or two kinds of arbitrary proportions in distilled water and the ethanol.
Wherein, described slow releasing agent is the mixture of any one or two kinds of arbitrary proportions in ethyl cellulose, cellulose acetate and the polyacrylic resin.
Wherein, the unit formulation content of described bromocriptine is 1～15mg, and preferred unit formulation content is 2～5mg.
Wherein, the unit formulation content of described metformin hydrochloride is 100～2000mg, and the preferred unit formulation content is 125～1500mg.
More preferably, the unit formulation content of described bromocriptine and metformin hydrochloride is combined as: 3.5mg and 375mg, or, 3.5mg and 400mg, or, 3.5mg and 450mg.
The preparation of drug combination method of above-mentioned treatment diabetes is with bromocriptine and metformin hydrochloride mix homogeneously, adds acceptable accessories, prepares various peroral dosage forms according to the conventional formulation method.
Beneficial effect: the pharmaceutical composition of treatment diabetes of the present invention mainly is to utilize the complementary synergism of two kinds of principal agents to reduce hyperglycemia, respectively the mark of hyperglycemia is brought into play therapeutical effect simultaneously with this according to two kinds of different pharmacological actions, for taking the out of contior type 2 diabetes mellitus of other compounds of metformin hydrochloride or metformin hydrochloride separately extraordinary curative effect is arranged, greatly reduce side effect, simultaneously cheap than other compound antihypelipidemic drug prices, made things convenient for the patient, can take the long period.Therefore the clinical treatment for type 2 diabetes mellitus has very important significance, and has demand widely in the patient.
The specific embodiment
According to following embodiment, the present invention may be better understood.Yet, those skilled in the art will readily understand that the described concrete material proportion of embodiment, process conditions and result thereof only are used to illustrate the present invention, and should also can not limit the present invention described in detail in claims.
Embodiment 1:
A kind of pharmaceutical composition for the treatment of diabetes comprises following component by mass percent:
Bromocriptine 0.7%,
Metformin hydrochloride 90%,
Lactose one water thing 8%,
Magnesium stearate 1.3%,
Production method is as follows:
Bromocriptine, metformin hydrochloride are crossed 80 mesh sieves respectively, mix homogeneously, the employing equivalent method of progressively increasing adds magnesium stearate after fully stirring and making evenly, divides the capsule of packing into No. 1 behind the mix homogeneously.The unit capsule contains bromocriptine 3.5mg, metformin hydrochloride 450mg.
Used capsule shells can be conventional capsule, also can be enteric coated capsule.
Embodiment 2:
A kind of pharmaceutical composition for the treatment of diabetes comprises following component by mass percent:
Bromocriptine 0.7%,
Metformin hydrochloride 80%,
Microcrystalline Cellulose 12%,
Hydroxypropyl emthylcellulose 5.8%,
Micropowder silica gel 0.8%,
Magnesium stearate 0.7%.
Production method is as follows:
Bromocriptine, microcrystalline Cellulose, hydroxypropyl emthylcellulose are crossed 80 mesh sieves respectively, and mix homogeneously adopts the equivalent method of progressively increasing to mix with metformin hydrochloride, fully stirs to make evenly, and is standby; 50% alcoholic solution is joined in the mixed powder, the system soft material, 24 mesh sieves are granulated, drying, 20 mesh sieve granulate add micropowder silica gel, magnesium stearate, adopt behind the mix homogeneously to be fit to the punch die compressed tablets, promptly.The unit tablet contains bromocriptine 3.5mg, metformin hydrochloride 400mg.
If carry out coating for above-mentioned tablet, then obtain coated tablet, can be gastric soluble tablet, enteric coatel tablets etc.
Embodiment 3:
A kind of pharmaceutical composition for the treatment of diabetes comprises following component by mass percent:
Bromocriptine 0.7%,
Metformin hydrochloride 75%,
Ethyl cellulose 15.8%,
Polyacrylic resin 8.5%,
The slow releasing tablet technology slow releasing tablet that is made into required specification gets final product routinely.The unit slow releasing tablet contains bromocriptine 3.5mg, metformin hydrochloride 375mg.
Embodiment 4: pharmacological evaluation.
1, by setting up the experimental technique of measuring sugared concentration in the Beagle dog blood, serves as the hypoglycemic activity that contrast preparation of the present invention is investigated in contrast, the results are shown in Table 1 with commercially available metformin hydrochloride tablet, glibenclamide sheet and parlodel tablet.
Respectively organize the horizontal situation of Beagle dog blood glucose value after table 1 administration
As seen from Table 1, by the Beagle dog of basic identical blood sugar concentration being given the hypoglycemic medicine of equal number, its result shows that the blood sugar concentration of Beagle dog has obvious difference behind the 2h, shows that the blood sugar lowering therapeutic effect of preparation of the present invention is better than commercially available metformin hydrochloride tablet, glibenclamide sheet and parlodel tablet.
2, by setting up the experimental technique of measuring sugared concentration in the Beagle dog blood, with other commercially available compound preparations in contrast, investigate the side effect of contrast preparation of the present invention, the results are shown in Table 2.
Respectively organize the horizontal situation of Beagle dog blood glucose value after table 2 administration
As seen from Table 2, give the commercially available various compound hypoglycemic agent 2h of common dose after blood sugar concentration obviously on the low side, the hypoglycemia phenomenon promptly appears, (normal range: 3.9～7.8mmol/L).
Claims (8)
1. a pharmaceutical composition for the treatment of diabetes is characterized in that, it comprises bromocriptine and metformin hydrochloride.
2. the pharmaceutical composition of treatment diabetes according to claim 1 is characterized in that it comprises acceptable accessories, makes peroral dosage form.
3. the pharmaceutical composition of treatment diabetes according to claim 2 is characterized in that, described dosage form is any one solid dosage forms in capsule, gastric soluble tablet, enteric coatel tablets and the slow releasing tablet.
4. according to the pharmaceutical composition of any described treatment diabetes in the claim 1 to 3, it is characterized in that the unit formulation content of described bromocriptine is 1～15mg.
5. the pharmaceutical composition of treatment diabetes according to claim 4 is characterized in that, the unit formulation content of described bromocriptine is 2～5mg.
6. according to the pharmaceutical composition of any described treatment diabetes in the claim 1 to 3, it is characterized in that the unit formulation content of described metformin hydrochloride is 100～2000mg.
7. the pharmaceutical composition of treatment diabetes according to claim 6 is characterized in that, the unit formulation content of described metformin hydrochloride is 125～1500mg.
8. according to the pharmaceutical composition of any described treatment diabetes in claim 5 or 7, it is characterized in that the unit formulation content of described bromocriptine and metformin hydrochloride is combined as: 3.5mg and 375mg, or, 3.5mg with 400mg, or, 3.5mg and 450mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101319260A CN102188429A (en) | 2011-05-20 | 2011-05-20 | Medicinal composition for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101319260A CN102188429A (en) | 2011-05-20 | 2011-05-20 | Medicinal composition for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102188429A true CN102188429A (en) | 2011-09-21 |
Family
ID=44597864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101319260A Pending CN102188429A (en) | 2011-05-20 | 2011-05-20 | Medicinal composition for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102188429A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104013971A (en) * | 2014-06-23 | 2014-09-03 | 深圳翰宇药业股份有限公司 | Bromocriptine composition sustained-release preparation and preparation method thereof |
| JP2015503582A (en) * | 2012-01-06 | 2015-02-02 | エルセリクス セラピューティクス インコーポレイテッド | Biguanide compositions and methods of treating metabolic disorders |
| US9463170B2 (en) | 2011-01-07 | 2016-10-11 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| US9481642B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| US9770422B2 (en) | 2012-01-06 | 2017-09-26 | Elcelyx Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| US10668031B2 (en) | 2011-01-07 | 2020-06-02 | Anji Pharma (Us) Llc | Biguanide compositions and methods of treating metabolic disorders |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101590058A (en) * | 2009-07-02 | 2009-12-02 | 苏州东瑞制药有限公司 | The pharmaceutical composition that contains dihydroergocryptine A mesylate |
-
2011
- 2011-05-20 CN CN2011101319260A patent/CN102188429A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101590058A (en) * | 2009-07-02 | 2009-12-02 | 苏州东瑞制药有限公司 | The pharmaceutical composition that contains dihydroergocryptine A mesylate |
Non-Patent Citations (2)
| Title |
|---|
| 张春芳等: "溴隐亭降糖作用的临床研究", 《中国现代应用药学杂志》 * |
| 黄胜炎: "糖尿病治疗药研发新进展", 《上海医药》 * |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10028923B2 (en) | 2011-01-07 | 2018-07-24 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US9463170B2 (en) | 2011-01-07 | 2016-10-11 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| US10154972B2 (en) | 2011-01-07 | 2018-12-18 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US10159658B2 (en) | 2011-01-07 | 2018-12-25 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US9962344B2 (en) | 2011-01-07 | 2018-05-08 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| US11065215B2 (en) | 2011-01-07 | 2021-07-20 | Anji Pharma (Us) Llc | Biguanide compositions and methods of treating metabolic disorders |
| US9481642B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US10201511B2 (en) | 2011-01-07 | 2019-02-12 | Elcelyx Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| US10668031B2 (en) | 2011-01-07 | 2020-06-02 | Anji Pharma (Us) Llc | Biguanide compositions and methods of treating metabolic disorders |
| US10610500B2 (en) | 2011-01-07 | 2020-04-07 | Anji Pharma (Us) Llc | Chemosensory receptor ligand-based therapies |
| US10603291B2 (en) | 2012-01-06 | 2020-03-31 | Anji Pharma (Us) Llc | Compositions and methods for treating metabolic disorders |
| JP2015503582A (en) * | 2012-01-06 | 2015-02-02 | エルセリクス セラピューティクス インコーポレイテッド | Biguanide compositions and methods of treating metabolic disorders |
| US9770422B2 (en) | 2012-01-06 | 2017-09-26 | Elcelyx Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| CN104013971A (en) * | 2014-06-23 | 2014-09-03 | 深圳翰宇药业股份有限公司 | Bromocriptine composition sustained-release preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102188429A (en) | Medicinal composition for treating diabetes | |
| CN103301084B (en) | Berberine hydrochloride tablet and preparation method thereof | |
| CN1486698A (en) | Solid oral dosage form containing metformin and glyburide | |
| CN105769792A (en) | A tablet containing a 1-(beta-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound | |
| CN106924208A (en) | A kind of compound Dapagliflozin Metformin Extended-release Tablets and preparation method thereof | |
| CN103070864B (en) | Repaglinide and metformin hydrochloride medicinal composition and its preparation method | |
| WO2023078180A1 (en) | Mini-tablet, and preparation method therefor and formulation thereof | |
| CN101420937A (en) | The manufacture method of extended release tablet | |
| KR20140019445A (en) | Compound chemical medicine acting on respiratory disease, preparation process and use thereof | |
| CN105233300A (en) | Stable vildagliptin composition and preparation method thereof | |
| CN101990427A (en) | Combination of mitiglinide and metformin and process for preparing same | |
| CN108699020A (en) | Dapagliflozin novel crystal forms and its preparation method and application | |
| CN100544722C (en) | The levodropropizine pharmaceutical composition that uses in a kind of oral cavity | |
| CN102119931A (en) | Novel metformin hydrochloride slow-releasing tablet and preparation method thereof | |
| CN101121004B (en) | Medicine composition containing insulin intensifier and miglitol | |
| CN109010298B (en) | Metformin and glipizide compound composition and preparation method thereof | |
| CN103251594A (en) | Repaglinide/metformin combo tablet | |
| CN107080741A (en) | Pirfenidone sustained release preparation and preparation method | |
| CN103251593A (en) | Repaglinide/metformin composition | |
| CN103271907B (en) | Oral medicine composition consisting of berberine and melbine, and preparation method thereof | |
| CN102727894A (en) | Pharmaceutical composition for treating diabetes and its complications and application thereof | |
| CN104771400A (en) | Oral pharmaceutical composition of diacerein and berberine, and applications thereof | |
| CN113616613A (en) | Metformin-glipizide compound tablet for treating diabetes and preparation method thereof | |
| CN1331470C (en) | Method for preparing high stripping-degree hautriwaic glipizide capsule | |
| CN111135150A (en) | Preparation method of glimepiride tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110921 |